Navigation Links
Video: Provectus PV-10 Interim Phase 2 Safety and Efficacy Results are as Good as or Better than Phase 1 Results
Date:3/16/2009

- Lead Investigator Professor John F. Thompson Presented Results at The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies in New York City -

- Detailed Efficacy Data to be Presented at ASCO May 29-June 2, 2009 -

KNOXVILLE, Tenn., March 16 /PRNewswire-FirstCall/ -- Provectus Pharmaceuticals, Inc. (OTC Bulletin Board: PVCT), a development-stage oncology and dermatology biopharmaceutical company, announced that the interim safety and efficacy results from the first 20 subjects in its Phase 2 clinical trial for the treatment of metastatic melanoma are as good as or better than Phase 1 data. Additionally, extended Phase 1 survival data was reported.

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/pvct/37429/

The lead investigator for Provectus' Phase 2 study of PV-10 for metastatic melanoma, Professor John F Thompson, MD, presented the update on Provectus' development efforts at The Sixth International Symposium on Melanoma and Other Cutaneous Malignancies on March 13, 2009 in New York City. A detailed analysis of the interim Phase 2 study results will be made available at the 2009 American Society of Clinical Oncology (ASCO) Scientific Program on May 29 - June 2, 2009 in Orlando, Florida."

Commenting on extended long-term survival data now available for subjects who participated in the Phase 1 study, Thompson noted, "There was an improvement in survival for those subjects achieving an objective response of their injected lesions, with a mean survival of 34.8 months as of early March, compared with a mean survival of 29.7 months calculated in October 2008. These results are even more interesting when one looks at disease-specific survival, where the mean for the response-positive group has increased to 37.3 months. This indicates tha
'/>"/>

SOURCE Provectus Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression
3. Video: The Arizona Heart Institute Announces the Largest Worldwide Experience with Endoluminal Grafting to Treat Thoracic Aortic Aneurysms and Related Pathologies
4. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
5. Video: Quest Diagnostics Health Trends(TM) Report Shows Significant Gap in Care for Patients With Chronic Kidney Disease
6. Video: New Results From One of the Worlds Largest Breast Cancer Trials Herald Hope for Thousands of Women
7. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
8. Video: The Journal, Human Genetics, Publishes Results Supporting Interleukin Genetics Heart Health Test
9. Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa(R) in Women With Early-Stage Breast Cancer
10. Video: Clinical Study Shows Liraglutide Reduced Blood Sugar, Weight, and Blood Pressure in Patients with Type 2 Diabetes
11. Video: Sanford Healths Journey to Cure Type 1 Diabetes Receives Major Boost
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/26/2015)... , March 26, 2015 Zimmer Holdings, Inc. ... new mobile app designed to serve as a feature-rich resource ... product. For those experiencing knee pain, the ... about the causes of knee pain and helps them understand ... a safe and simple non-surgical treatment option. For those who ...
(Date:3/26/2015)... , March 26, 2015  RegeneRx Biopharmaceuticals, Inc. (OTCQB: ... received a patent acceptance notice from the Israeli patent ... to prevent or reduce tissue damage caused by an ... when cardiac vessels are opened after a blockage causing ... stroke victims. Damage can be caused to ...
(Date:3/26/2015)... InfuSystem Holdings, Inc. (NYSE MKT: INFU), a leading ... healthcare industry in the United States ... secured a new $45.0 million credit facility with JPMorgan Chase ... facility with its prior lender group.  Effective ... senior secured credit agreement comprised of a $10.0 million asset-based ...
Breaking Medicine Technology:Zimmer Launches New Patient Education And Engagement Mobile App For Gel-One Hyaluronate 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 2RegeneRx Receives Israeli Patent Acceptance Notice for the Use of TB4 To Prevent Tissue Damage Associated with Heart Attack and Stroke Treatments 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 2InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 3InfuSystem Announces New $45 Million Credit Facility At Substantially Lower Rates 4
... NEW YORK, Feb. 15, 2011 Reportlinker.com ... is available in its catalogue: ... CE countries 2011 - Comparative analysis, reimbursement ... http://www.reportlinker.com/p0395681/Generic-and-innovative-drug-market-in-CE-countries-2011---Comparative-analysis-reimbursement-policies-and-development-forecasts-for-2011-2013 ...
... 15, 2011 Valeant Pharmaceuticals International, Inc. (NYSE: ... a conference call and a live Internet webcast along with ... a.m. ET (7:00 a.m. PT) to discuss results for the ... number to participate on this call is (877) 295-5743, confirmation ...
Cached Medicine Technology:Reportlinker Adds Generic and innovative drug market in CE countries 2011 - Comparative analysis, reimbursement policies and development forecasts for 2011-2013 2Valeant Pharmaceuticals to Announce 2010 Fourth Quarter and Full Year Results on February 24, 2011 2
(Date:3/26/2015)... (PRWEB) March 26, 2015 The American College ... be on the topics of the DAOM Program as well ... Program Overview Webinar will be hosted by Dr. Carla Wilson, ... the next steps on how to prepare for the spring ... March 25, March 27, April 1 and April 3. Attendees ...
(Date:3/26/2015)... (PRWEB) March 26, 2015 The Baruch ... new team of nationally renowned scientists to focus exclusively ... a move that nearly triples its research capacity and ... solely on hepatitis B and liver cancer in the ... Block, Jinhong Chang, Ju Tao Guo and Ying-Hsiu Su ...
(Date:3/26/2015)... 26, 2015 Visiting Nurse Association ... 18th annual gala fundraiser, Lighting the Way, Brightening the ... at The Madison Hotel in Morristown, NJ. , ... by renowned musician Rio Clemente, delightful cuisine, an extensive ... Dave Hertzel. Additionally, two prestigious awards will be presented ...
(Date:3/26/2015)... NY (PRWEB) March 26, 2015 ... its 30th “Introduction to Hyperbaric Medicine” course, which ... Medical Society (UHMS) and the National Board of ... provides the 40-hour course 4 times a year ... around the NY tri-state region; registration is available ...
(Date:3/26/2015)... March 26, 2015 On March 5, ... Matthews is out for the season with a torn ... while the Trail Blazers were competing against Dallas, and ... specialist, Izzy Silva, M.D., who has treated many ... and whether it could be prevented. , "Part ...
Breaking Medicine News(10 mins):Health News:ACTCM Announces Upcoming Webinars 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 2Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 3Health News:Baruch S. Blumberg Institute Recruits World-Class Hepatitis B Scientists 4Health News:Morristown VNA Fundraiser to Honor Distinguished Community Members 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 2Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 3Health News:The Life Support Technologies Group (LST) Conducted its 30th Accredited “Introduction to Hyperbaric Medicine” Course for Health Care Professionals 4Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 2Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 3Health News:Sports Medicine Specialist Weighs In on Wesley Matthew’s Significant Tendon Injury; Can it be Prevented? 4
... the U.S. Department of Agriculture found that a compound in ... compound, pterostilbene, is a potent antioxidant that could be developed ... effects than some commercial drugs that are currently used to ... cause of cancer death in the United States. ...
... discovered by researchers at Weill Cornell Medical College could prove ... ,The compound, called SS31, is able to cross the ... to stroke-related tissue damage. ,"In our experiments, we ... stroke led to a much smaller area of brain tissue ...
... specially developed proteins could make our bodies more resistant ... ,Steaks and chicken fillets laced with some ... against oxidation – oxidation is considered a major cause ... Shchepinov, a former Oxford University scientist, has found ...
... University of Wisconsin-Madison claim that they can efficiently seek ... cells//. This is very similar to the Nature's way ... ,The new tumor targeting strategy, presented today (March ... Chemical Society, cleverly harnesses one of the body's natural ...
... wisdom, in order to deal with teenage pregnancies and ... ,Improving pupil-teacher relationships and raising a teenager’s self-confidence ... will do the trick, say the researchers. In this ... newer ones such as focusing on sexual risks ,and ...
... the omega-3 fatty acids docosahexaenoic acid (DHA) successfully reduced ... trial, backing up previous results with higher doses. // ... which is likely to be of clinical significance with ... subjects," wrote lead author Hannah Theobald from King's College ...
Cached Medicine News:Health News:Eat Berries, Prevent Colon Cancer 2Health News:Eat Berries, Prevent Colon Cancer 3Health News:Antioxidant Molecule Could Help Minimize Stroke-Linked Brain Damage 2Health News:Tumors Targeted Naturally 2Health News:Tumors Targeted Naturally 3Health News:'School Sermons' Need a Comeback 2Health News:Low-dose Omega-3 Linked to Lower Blood Pressure 2
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: